Association Between Atopic Dermatitis and Systemic Immune‐Inflammation Index: Evidence From NHANES 1999–2006

Elevated SII is independently associated with increased AD risk. Although the cross-sectional design precludes causal inference, SII represents a cost-effective biomarker for AD risk stratification. Critically, emerging evidence positions SII as a predictor of therapeutic response-particularly to JAK inhibitors and biologics-highlighting its dual utility in risk assessment and precision management of AD.